| [1] |
Bomanji JB, Costa DC, Ell PJ. Clinical role of positron emission tomography in oncology[J]. Lancet Oncol, 2001, 2(3):157-164.
|
| [2] |
Schmiolt D, Gottand U, Langen KJ, et al. 3-[123] Iodoalpha-methyl-L-tyrosine uptake in cerebral gliomas:relationship to histological grading and prognosis[J]. Eur J Nucl Med, 2001, 28(7):855-861.
|
| [3] |
Tomiyoshi K, Amed K, Muhammad S, et al. Synthesis of isomers of 18F-labelled amino acid radiopharmaceutical:position 2- and 3-L-18F-alpha-methyltyrosine using a separation and purification system[J]. Nucl Med Commun, 1997,18(2):169-175.
|
| [4] |
Inoue T, Tomiyoshi K, Higuchi T, et al. Biodistribution studies on L-3-[fluorine-18]fluoro-alpha-methyl tyrosine:a potential tumor-detecting agent[J]. J Nucl Med,1998, 39(4):663-667.
|
| [5] |
Tomiyoshi K, Inoue T, Higuchi T, et al. Metabolic studies of [18F-alpha-methyl]tyrosine in mice bearing colorectal carcinoma LS180[J]. Anticancer Drugs, 1999, 10(3):329-336.
|
| [6] |
Amano S, Inoue T, Tomiyoshi K, et al. In vivo somparison of PET and SPECT radiopharmaceuticals in detecing breast cancer[J]. J Nucl Med, 1998, 39(8):1424-1427.
|
| [7] |
Inoue T, Koyama K, Oriuchi N, et al. Detection of malignant tumors:whole-body PET with fluorine-18 alpha-methyl tyrosine versus FDG-prelimary study[J]. Radiology, 2001, 220(10):54-62.
|
| [8] |
Inoue T, Shibasaki T, Oriuchi N, et al. 18F-alpha-methyl tyrosine PET stidies in patients with brain tumors[J]. J Nucl Med, 1999, 40(3):399-405.
|
| [9] |
Watanabe H, Inoue T, Shinozali T, et al. PET imaging of musculoskeletal tumors with fluorine-18 alpha-methyltyrsine:comparison with fluorine-18 fluorodeoxyglucose PET[J]. Eur J Nucl Med, 2000, 27(10):1509-1517.
|